Agios Pharmaceuticals AGIO Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's total costs & expenses?
- Agios Pharmaceuticals (AGIO) reported total costs & expenses of $130.77M in Q1 2026.
- How has Agios Pharmaceuticals's total costs & expenses changed year-over-year?
- Agios Pharmaceuticals's total costs & expenses increased by 13.4% year-over-year, from $115.36M to $130.77M.
- What is the long-term trend for Agios Pharmaceuticals's total costs & expenses?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's total costs & expenses has grown at a 8.6% compound annual growth rate (CAGR), from $378.42M to $526.16M.
- What does total costs & expenses mean?
- This metric represents the aggregate sum of all operating and non-operating costs incurred by the company during a reporting period, including research and development, selling, general, and administrative expenses. It serves as a comprehensive measure of the total capital outflow required to sustain business operations and advance the clinical development pipeline. Monitoring this figure is essential for assessing the company's overall cost structure and operational efficiency relative to its revenue generation.